Joi + Blokes Review: A Peptide Seller That Quantifies Results It Cannot Cite

The claim that can actually be checked

Almost all peptide marketing is written to be uncheckable. "May support." "Helps promote." "Part of a healthy lifestyle." You cannot falsify a hedge, which is the point of one.

Joi + Blokes does something different on its sermorelin page, and it deserves to be taken seriously for it. In the FAQ, under "What benefits should I expect to see (and when) from Sermorelin?", the answer walks month by month and lands here: "By month six, studies suggest potential 5-10% body fat reduction (without diet or exercise), a 10% increase in lean muscle mass, and improved overall vitality."

That is a real claim. It has two numbers, a timeframe, a stated mechanism of attribution — studies — and a parenthesis that removes the usual escape route by specifying that the change happens without diet or exercise. It can be checked. So it was.

As of August 2026, a PubMed search for sermorelin filtered to the randomised-controlled-trial publication type returns 19 records. The newest was published in 2005. ³ They are studies of growth hormone response to a challenge, of growth in children with growth hormone deficiency, of dose-response to a low-dose bolus, of what happens when you block the GHRH receptor. Not one of them reports a body-fat percentage. Not one reports a lean-mass change. Not one runs for six months in healthy adults, because that is not the question anyone was asking.

ClinicalTrials.gov gives the same answer from the registry side. Twenty-seven studies list sermorelin as an intervention. The two that come closest to the marketed use — NCT01410799, three months of GHRH in the elderly, and NCT00807365, the six-month version — are both phase 2 and both TERMINATED, having enrolled 13 and 5 participants respectively.

So the honest description of "studies suggest potential 5-10% body fat reduction" is that no study suggests it, because no study has looked. This site's editorial policy has a line about exactly this construction: "'Studies suggest', 'research shows', and 'experts agree' are not evidence — they are ways of avoiding a citation." What is unusual here is that the avoidance comes with a number attached, which makes it worse and easier to check at the same time.

None of this means sermorelin does nothing, and this review does not say it is unsafe. It is a growth-hormone-releasing hormone analogue and it does stimulate pituitary GH release — that mechanism is well established, and it is why the drug existed as a diagnostic agent. The gap is between a mechanism and an outcome, and it is the whole gap.

VIP, and a literature about a different question

The second peptide is stranger, because the evidence base is substantial and points somewhere else entirely.

The product is vasoactive intestinal peptide as a nasal spray, $159 a month on subscription. The page's bullets: "Supports immune function. Reduces inflammation. Optimizes gut health. Supports joint health and mobility. Balances stress response. Supports cognitive function." Above them, a paragraph that is straightforwardly correct — VIP "is composed of 28 amino acid residues and is known to have numerous effects on development, growth, and the function of neuronal, epithelial, and endocrine cells."

That paragraph is textbook pharmacology and it is doing rhetorical work rather than evidential work. The bullets are the claim, and "reduces inflammation" is stated flatly, without the hedging every other line carries.

As of August 2026, ClinicalTrials.gov lists 19 studies with vasoactive intestinal peptide as an intervention. ⁴ They sort into four groups and none is about wellness. There is a headache-research group, where VIP is infused into volunteers deliberately to *induce* migraine and study the mechanism. There is a pulmonary arterial hypertension group built around pemziviptadil, a long-acting VIP analogue, whose phase 2 trials were both terminated. There is a severe-COVID group built around aviptadil, including the phase 3 ACTIV-3b programme. And there is a small COPD group.

Serious science, real trials, substantial enrolments — and all of it concerns intravenous or inhaled administration in acutely ill patients for cardiopulmonary indications. Not one study concerns immunity, gut health, joint mobility, stress or cognition in a healthy adult, and none concerns a wellness nasal spray. Having a real literature about a different question is not the same as having evidence, and a reader who searches "VIP clinical trials" will find plenty of hits and draw exactly the wrong conclusion.

The page's social proof completes the picture. A customer testimonial reads: "Peptides have a really big anti-aging community. You may have heard of it from David Sinclair or Andrew Huberman. Some of the benefits I noticed right away are increased recovery, better mood, and more energy." Two names, neither of whom has published anything about a VIP nasal spray, standing in for the citation that is not there.

What the FDA letter says, and what it does not

On June 8, 2026, FDA wrote to Joi and Blokes after reviewing joiandblokes.com in March. Two allegations, both misbranding under sections 502(a) and 502(bb), both about advertising and labelling. ⁶

The first is now a familiar pattern across this enforcement wave: the compounded semaglutide and tirzepatide products pictured on the site "identify 'Joi + Blokes' on the pictured label, suggesting Joi + Blokes is the compounder of those drugs when in fact it is not."

The second is the substantive one, and FDA quotes the site directly: "By utilizing the same bioidentical compound as Ozempic and Wegovy, Blokes can provide a cost-effective alternative," and "At Blokes, we offer a cost-effective semaglutide option that is bioidentical with more expensive brands." FDA's answer is three sentences and worth reading slowly: "Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."

The mechanism is the word "bioidentical." It is true at the level of the molecule, and it quietly transfers the approval and the entire trial programme that belong to the finished product — 1,961 participants in STEP 1 for semaglutide ², 2,539 in SURMOUNT-1 for tirzepatide ¹ — onto a preparation that has never been in a trial. Nothing false is stated. The inference does all the work.

What the letter does not contain matters just as much. There is no allegation about sterility, potency, contamination or any other aspect of product quality. A warning letter is a public regulatory communication, not a finding of illegal activity, not an injunction and not a shutdown; firms across this wave have responded with corrective action and continued trading. It is disclosed here because a reader deciding where to spend $186 a month should know it exists, and it is not treated as disqualifying because it is not.

On the follow-up check: the word "bioidentical" does not appear on the men's sermorelin page, the men's VIP page or the storefront navigation as they stood on August 7, 2026. The compounded GLP-1 page itself returned a Cloudflare 403 to every request that day, so whether the quoted sentences survive there is unknown and this review does not guess.

The measurement paradox

Here is the thing that makes Joi + Blokes genuinely interesting rather than simply another peptide storefront.

The company's whole proposition is measurement. Its most prominent products are diagnostic panels: the Complete Hormone Panel at $149 covering 56 biomarkers, the Advanced Panel at $399 covering 71, the Comprehensive Panel at $699 covering 110. Rapamycin and enclomiphene carry a visible "Lab Required" flag. The homepage promise is "[d]ata-driven diagnostics and science-backed therapies." Prescriptions require a clinician, stated plainly: "All prescriptions require a consultation with a licensed provider, either asynchronously or synchronously."

That is a better intake than most of this market offers, and it is not marketing dressing — asking for 110 biomarkers before prescribing is a real cost the company chose to bear.

And then nothing is measured about the drug. Across the men's and women's sermorelin, VIP and NAD+ pages and the storefront navigation, searched on August 7, 2026, there is no potency tolerance, no sterility standard, no certificate of analysis, no laboratory named, and no pharmacy named. For comparison, the compounded-peptide seller reviewed alongside this one at least publishes its testing cadence — enough detail to reveal that its potency test runs every three to six months rather than per batch. Joi + Blokes publishes neither the cadence nor the standard.

So a customer is invited to quantify 110 things about their own body and given zero quantified facts about the vial. Whatever the panels are measuring, it is not the variable most likely to determine whether the treatment does anything.

The three prices

A smaller point, but the kind that tells you how carefully a page was assembled.

The site navigation lists, under Popular Products, "Sermorelin Peptide Therapy — Peptide associated with growth hormone signaling. $199/mo." The sermorelin product page offers exactly two ways to buy: $559 for a 12-week supply on subscription, which the page renders as $186.33 a month, or $699 one-time, rendered as $233 a month.

$199 is neither. It is not the subscription rate, it is not the one-time rate, and it is not an average of them. It appears on every page of the site as the price of the product, in the same navigation panel that correctly lists NAD+ at $150 and VIP at $159.

None of these figures is hidden and the product page is admirably explicit — showing the undiscounted price next to the subscription price is more than most competitors do. But a reader who decides to buy at the advertised $199 will be charged something else, in one direction or the other, depending on which option they pick.

What to take from this

The split in this company runs cleanly along one line: everything about the process is better than the category average, and everything about the claims is worse.

If you are here for the approved GLP-1s, the descriptions are accurate, the branded products are distinguished from the compounded ones, and you will be told which may be insurance-eligible. That is a competent service.

If you are here for the peptides, understand what you are buying. Sermorelin's mechanism is real and its outcomes are unstudied; the specific numbers on the page come from nowhere. VIP has a serious clinical literature about pulmonary hypertension and severe COVID-19 and none at all about the six things the bullets promise. NAD+ by injection has no randomised evidence, whatever the oral-precursor literature shows.

None of that means these molecules do nothing, and this site does not tell anyone what to take — the reconstitution tools here convert numbers and never suggest a dose, and what to do about any of this is a conversation with a clinician. It means the evidence is not what the page implies, and the page implies it with a precision that ought to be reserved for facts.